Becton, Dickinson and Company Generated Lower-Than-Expected Revenue in Q2

First Eagle Investments, an investment management company, released its “First Eagle Global Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Class A shares of the fund returned 7.23% in the second quarter of 2025. All regions contributed to the overall performance. North America and developed Europe were the top contributors, whereas Japan and developed Asia, excluding Japan, lagged. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its second-quarter 2025 investor letter, First Eagle Global Fund highlighted stocks such as Becton, Becton, Dickinson and Company (NYSE:BDX). Becton, Dickinson and Company (NYSE:BDX) is a healthcare company that develops and manufactures medical supplies, devices, laboratory equipment, and diagnostic products. The one-month return of Becton, Dickinson and Company (NYSE:BDX) was 7.29%, and its shares lost 20.63% of their value over the last 52 weeks. On August 28, 2025, Becton, Dickinson and Company (NYSE:BDX) stock closed at $191.25 per share, with a market capitalization of $54.817 billion.

First Eagle Global Fund stated the following regarding Becton, Dickinson and Company (NYSE:BDX) in its second quarter 2025 investor letter:

"The leading detractors in the quarter were Becton, Dickinson and Company (NYSE:BDX), SLB, Elevance Health, Inc., Alibaba Group Holding Ltd. and Willis Towers Watson Public Limited Company. Becton Dickinson develops and manufactures medical devices, instrument systems and reagents used in a variety of professional and public settings. The company reported lower-than-expected revenue for its most recent quarter because of weakness in its research instrument and diagnostics businesses resulting from lower global research spending and the impact of tariffs. We continue to like Becton Dickinson’s ability to generate cash and its commitment to enhancing shareholder value through stock buybacks and dividends."

Becton, Dickinson and Company (NYSE:BDX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 58 hedge fund portfolios held Becton, Dickinson and Company (NYSE:BDX) at the end of the second quarter, which was 54 in the previous quarter. In the fiscal third quarter of 2025, Becton, Dickinson and Company's (NYSE:BDX) revenue grew 8.5% to $5.5 billion or 3% organic. While we acknowledge the potential of Becton, Dickinson and Company (NYSE:BDX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Becton, Dickinson and Company (NYSE:BDX) and shared Kovitz Core Equity Strategy's views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.